Det danskgrundade bioteknikbolaget Pila Pharma, med säte i Malmö, siktar på uppköp eller partnerskap inom några år. Det kortsiktiga målet är att vidareutveckla en lovande ny läkemedelskandidat för tablettbaserad behandling av övervikt och diabetes.
The Danish-founded biotech company Pila Pharma looks to secure a partnership or acquisition within the next few years. The short-term goal is to advance the development of a promising new drug candidate for the treatment of obesity and diabetes.
The requirements for quality assurance of biologics are increasing. Danish contract laboratory now opens for access to a database that - combined with the company’s measurement tools - can shorten the development time and heighten the quality of novel biological products.